T he field of antiarrhythmic therapy is undergoing a number of new and exciting developments. Flecainide acetate (Tambocor®) is a recently approved antiarrhythmic agent which, although similar in some aspects to quinidine and pro cainamide, possesses some unique characteristics. The purpose of this review is to summarize the pharmacologic and physiologic effects of flecainide and to outline its clinical use.
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Electrophyslologlc Effects. Flecainide was developed by Riker Laboratories through the systematic alteration of procainamide molecules (Figure 1 ).1 Like procainamide, it is a potent local anesthetic agent that acts by slowing the rate of rise of the action potential upstroke due to its blockage of the inward sodium current. This produces a slowing of conduction and a lengthening of the QRS duration. 2 Electrophysiologic studies have demonstrated that flecainide produces a dose-related prolongation ofintracardiac conduction in all parts of the heart, an effect that is greatest in the His-Purkinje system, but effects AV nodal conduction as well.
•
4 These investigations have shown that flecainide prolonged the right intra-atrial conduction time (PA interval), AV nodal conduction time (AH interval) and HisPurkinje conduction time (H-V interval).5.6 However, as opposed to procainamide, flecainide does not prolong the duration of repolarization (a property that classifies it as a class Ic antiarrhythmic).
7 Thus, one sees prolongation of the PR and QRS intervals with flecainide with only minimal increases in the QT interval duration, which result largely from QRS prolongation. Although flecainide may exhibit significant pro arrhythmic effects, the arrhythmias that are sometimes seen in association with QT prolongation (long QT syndrome, torsade de pointes) frequently seen with quinidine,s are rare with flecainide and appear only at toxic dosages. 
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Pharmacoklnetlc Parameters. The pharmacology and pharmacokinetic parameters of flecainide have been studied for both oral and intravenous administration.
As with most drugs, the elimination of flecainide from plasma occurs in two stages. The first elimination phase is seen following intravenous administration. Here, plasma flecainide levels fall during the first 15 to 30 minutes, during which time the drug redistributes from the systemic circulation to the tissues. Afterward, during the terminal elimination phase, the rate of fall stabilizes and shows a slow decline. lO • ll The elimination of half-life of the drug in healthy subjects is 7 to 19 hours, with a mean half-life of 13 hours, when dosages of 0.5 to 2 mg/kg are administered intravenously.12
When flecainide is given orally, the drug is well absorbed and is nearly 100% bioavailable. lO Neither food nor antacids alter absorption, and increasing dosages result in a linear increase in plasma levels. 
